FDA Brief

Warning letters Drugs

FDA warning letter to

Imperial Palace Commodity -Dongguan- Co., Ltd.

High riskIssued Jan 27, 2025Posted Feb 4, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Chinese maker of OTC alcohol wipes that weak component testing and process validation make its drugs adulterated.

What happened

FDA did not inspect the plant; it reviewed records the company sent after FDA's March 4, 2024 request and later requests under section 704(a)(4) of the Food, Drug, and Cosmetic Act, which lets FDA demand records instead of visiting. The records showed the company did not test incoming ingredients for identity, including glycerin (not tested for diethylene glycol or ethylene glycol) and ethanol (not tested for methanol), relied on suppliers' certificates of analysis, did not properly validate its manufacturing process or water system, used a microbiological test method meant for preservatives in products that contain none, and did not have an effective quality unit. FDA placed the firm's products on Import Alert 66-40 on January 23, 2025.

What FDA found

  1. The company did not test each incoming ingredient to confirm what it was and that it met purity, strength and quality specifications, and it relied on suppliers' certificates of analysis without periodically checking that those supplier results were reliable.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The company did not test each shipment of each lot of glycerin for identity, including the USP test that detects diethylene glycol and ethylene glycol, and did not test its ethanol for methanol; contamination with these has caused fatal poisonings worldwide.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The company did not show it had validated the manufacturing process for its alcohol wipes; what it sent as process validation was only reports of analytical test results.

    21 CFR 211.100(a)
  4. The company did not show its water system was designed and validated for its intended use, and its validation report lacked total organic carbon test results, so it did not show the water meets USP specifications.

    21 CFR 211.100(a)
  5. The company used USP <51> Antimicrobial Effectiveness Testing, a method for showing added preservatives work, as its microbiological test method even though its products contain no preservatives, so its results do not support the microbiological specifications through expiry.

    21 CFR 211.160(b)
  6. The company's quality unit did not effectively use its authority to approve or reject materials or to set controls in its materials system and laboratory control system.

    21 CFR 211.22(a)

What FDA wants

FDA tells the company to correct the violations promptly and to reply in writing within 15 working days, saying what it has done and how it will prevent recurrence, or explaining any delay and giving a completion schedule. FDA also recommends hiring a qualified CGMP consultant to do a full six-system audit of the operation.

Who should pay attention

  • brands and distributors that buy OTC wipes from this contract manufacturer
  • companies that rely on supplier certificates of analysis instead of their own identity testing
  • US importers and own-label retailers of OTC drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk